Vol. 4 No. 6 (2024)
Reimbursement Recommendations

Nivolumab (Opdivo)

Published June 14, 2024

Key Messages

  • CADTH recommends that Opdivo should be reimbursed by public drug plans for the adjuvant treatment of adult patients with stage IIB or IIC melanoma following complete resection, only if certain conditions are met.
  • Opdivo should only be covered to treat patients who have stage IIB or IIC melanoma and have not received prior treatment beyond surgery.
  • Opdivo should only be reimbursed if prescribed in an outpatient oncology clinic and supervised and/or delivered in institutions with expertise in delivery of immunotherapy and if the cost of Opdivo is not more than the least costly adjuvant therapy currently funded for this population.